A detailed history of Rhumbline Advisers transactions in Mannkind Corp stock. As of the latest transaction made, Rhumbline Advisers holds 397,194 shares of MNKD stock, worth $2.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
397,194
Previous 377,519 5.21%
Holding current value
$2.96 Million
Previous $1.71 Million 21.23%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$4.05 - $5.43 $79,683 - $106,835
19,675 Added 5.21%
397,194 $2.07 Million
Q1 2024

May 09, 2024

BUY
$3.25 - $5.27 $25,762 - $41,775
7,927 Added 2.14%
377,519 $1.71 Million
Q4 2023

Feb 08, 2024

SELL
$3.34 - $4.29 $40,667 - $52,235
-12,176 Reduced 3.19%
369,592 $1.35 Million
Q3 2023

Nov 09, 2023

BUY
$3.91 - $5.45 $22,036 - $30,716
5,636 Added 1.5%
381,768 $1.58 Million
Q2 2023

Aug 08, 2023

SELL
$3.72 - $4.79 $133,164 - $171,467
-35,797 Reduced 8.69%
376,132 $1.53 Million
Q1 2023

May 11, 2023

BUY
$3.95 - $5.63 $64,116 - $91,386
16,232 Added 4.1%
411,929 $1.69 Million
Q4 2022

Feb 14, 2023

BUY
$3.02 - $5.37 $29,139 - $51,815
9,649 Added 2.5%
395,697 $2.09 Million
Q3 2022

Nov 10, 2022

BUY
$2.99 - $4.35 $71,362 - $103,821
23,867 Added 6.59%
386,048 $1.19 Million
Q2 2022

Aug 11, 2022

BUY
$2.67 - $4.77 $124,189 - $221,867
46,513 Added 14.73%
362,181 $1.38 Million
Q1 2022

May 12, 2022

SELL
$2.62 - $4.45 $54,582 - $92,706
-20,833 Reduced 6.19%
315,668 $1.16 Million
Q4 2021

Feb 10, 2022

SELL
$4.05 - $5.37 $12,044 - $15,970
-2,974 Reduced 0.88%
336,501 $1.47 Million
Q3 2021

Nov 12, 2021

BUY
$3.89 - $5.48 $41,109 - $57,912
10,568 Added 3.21%
339,475 $1.48 Million
Q2 2021

Aug 05, 2021

BUY
$3.61 - $5.45 $348,837 - $526,638
96,631 Added 41.6%
328,907 $1.79 Million
Q1 2021

May 06, 2021

SELL
$3.14 - $6.14 $40,663 - $79,513
-12,950 Reduced 5.28%
232,276 $911,000
Q4 2020

Feb 10, 2021

BUY
$1.79 - $4.04 $31,128 - $70,255
17,390 Added 7.63%
245,226 $768,000
Q3 2020

Nov 12, 2020

SELL
$1.56 - $2.08 $57,135 - $76,180
-36,625 Reduced 13.85%
227,836 $428,000
Q2 2020

Aug 13, 2020

BUY
$0.94 - $2.21 $26,774 - $62,947
28,483 Added 12.07%
264,461 $463,000
Q4 2019

Feb 05, 2020

BUY
$1.14 - $1.49 $1,868 - $2,442
1,639 Added 0.7%
235,978 $304,000
Q3 2019

Oct 23, 2019

SELL
$1.04 - $1.44 $1,612 - $2,232
-1,550 Reduced 0.66%
234,339 $293,000
Q2 2019

Aug 14, 2019

BUY
$1.09 - $1.88 $37,103 - $63,995
34,040 Added 16.86%
235,889 $271,000
Q1 2019

May 01, 2019

BUY
$1.14 - $2.25 $21,783 - $42,993
19,108 Added 10.46%
201,849 $398,000
Q4 2018

Jan 31, 2019

BUY
$1.02 - $2.05 $61,825 - $124,256
60,613 Added 49.63%
182,741 $194,000
Q3 2018

Nov 07, 2018

SELL
$1.01 - $2.19 $9,216 - $19,983
-9,125 Reduced 6.95%
122,128 $223,000
Q2 2018

Aug 06, 2018

BUY
$1.59 - $2.38 $208,692 - $312,382
131,253 New
131,253 $249,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.91B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.